Parylene scaffold for cartilage lesion

• Published in: Biomedical microdevices 2017-06, Vol.19 (2), p.26-11, Article 26
• Main Authors: Franciozi, Carlos Eduardo da Silveira, Vangsness, Carleton Thomas, Tibone, James Eugene, Martinez, Juan Carlos, Rodger, Damien, Chou, Tzu-Chieh, Tai, Yu-Chong, Brant, Rodrigo, Wu, Ling, Abdalla, Rene Jorge, Han, Bo, Evseenko, Denis, Humayun, Mark
• Format: Article
• Language: English
• Subjects: Animals; Biocompatibility; Biological and Medical Physics; Biomedical Engineering and Bioengineering; Biomedical materials; Biophysics; Cartilage; Cartilage Diseases - diagnostic imaging; Cartilage Diseases - pathology; Cartilage Diseases - therapy; Collagen (type II); Collagens; Engineering; Engineering Fluid Dynamics; Evaluation; Feasibility Studies; Femur - diagnostic imaging; Femur - drug effects; Femur - pathology; Knee; Knees; Lateral control; Lesions; Male; Nanotechnology; Polymers - pharmacology; Rabbits; Repair; Scaffolds; Surgery; Tissue engineering; Tissue Scaffolds; Xylenes - pharmacology
• ISSN: 1387-2176; 1572-8781
• DOI: 10.1007/s10544-017-0170-7

Evaluate parylene scaffold feasibility in cartilage lesion treatment, introducing a novel paradigm combining a reparative and superficial reconstructive procedure. Fifteen rabbits were used. All animals had both knees operated and the same osteochondral lesion model was created bilaterally. The parylene scaffold was implanted in the right knee, and the left knee of the same animal was used as control. The animals were euthanized at different time points after surgery: four animals at three weeks, three animals at six weeks, four animals at nine weeks, and four animals at 12 weeks. Specimens were analyzed by International Cartilage Repair Society (ICRS) macroscopic evaluation, modified Pineda histologic evaluation of cartilage repair, and collagen II immunostaining. Parylene knees were compared to its matched contra-lateral control knees of the same animal using the Wilcoxon matched-pairs signed rank. ICRS mean ± SD values for parylene versus control, three, six, nine and twelve weeks, respectively: 7.83 ± 1.85 versus 4.42 ± 1.08, p  = 0.0005; 10.17 ± 1.17 versus 6.83 ± 1.17, p  = 0.03; 10.89 ± 0.60 versus 7.33 ± 2.18, p  = 0.007; 10.67 ± 0.78 versus 7.83 ± 3.40, p  = 0.03. Modified Pineda mean ± SD values for parylene versus control, six, nine and twelve weeks, respectively: 3.37 ± 0.87 versus 6.94 ± 1.7, p